CLINICAL TRIAL TO DETERMINE WORTH OF TAMOXIFEN FOR BREAST CANCER PREVENTION

该研究是一项多中心随机试验，旨在确定他莫昔芬 每天服用20毫克可降低患乳腺癌的风险 与安慰剂相比。有资格参加这项研究的女性包括超过 60岁或35至59岁的女性，估计有罹患癌症的风险 类似于60岁女性的乳腺癌。 超过50名妇女接受了筛查，5名妇女被随机分配。这个 大多数女性拒绝参与，因为任何一方都有可能 他莫昔芬的疗效或希望继续雌激素替代 心理治疗。一名妇女因患上子宫症而退出研究 癌症。另一名女性因该药的副作用而退出研究。 学习药片。审判的期限至少为10年。 在为审判招募人员的过程中，我们能够 确定适合参加病例对照分子研究的妇女 乳腺癌易感因素的流行病学研究。

The study is a multi-center randomized trial to determine if tamoxifen in a daily dose of 20 mg reduces the risk of developing breast cancer compared to placebo. Women eligible for the study include women over the age of 60 or women 35 to 59 who have an estimated risk of developing breast cancer similar to that of a 60 year old woman. Over 50 women have been screened and 5 have been randomized. The majority of women refuse participation because of either potential side effects of tamoxifen or the wish to continue estrogen replacement therapy. One woman is now off the study after developing uterine cancer. Another woman went off the study because of side effects of the study pills. The duration of the trial is for at least 10 years. In the process of recruiting for the trial, we have been able to identify women appropriate for participation in a case-control molecular epidemiologic study of susceptibility factors to breast cancer.